%PDF-1.3
%
10 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
13 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 134>>stream
xA0}O1K]+5 zhJ)K7'V8ԚvV݈ WwTؔH)mWA?
:X\\% e8墳
'j
endstream
endobj
15 0 obj
<>stream
2018-09-21T12:17:21+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2018-09-27T00:24:28-07:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
application/pdf
ACM-2018-0191-ver9-Jong_3P 942..953
uuid:8764abd9-f7f2-483c-b68e-30a3b22e873f
uuid:12538db0-1ed6-4839-a9c2-a4201ded06a5
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bih lT
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
28 0 obj
<>stream
x+ |
endstream
endobj
29 0 obj
<>stream
xS**T0T0 Bih uU
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
34 0 obj
<>stream
x+ |
endstream
endobj
35 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
36 0 obj
<>stream
x+ |
endstream
endobj
37 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
38 0 obj
<>stream
x+ |
endstream
endobj
39 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
41 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
(Introduction)Tj
/F11 1 Tf
26.1167 0 0 26.1167 58.7905 693.014 Tm
(A)Tj
/F12 1 Tf
9.843 0 0 9.843 78.5197 703.8423 Tm
[(s)-363.8(the)-361.6(number)]TJ
/F5 1 Tf
6.4854 0 TD
[(of)-365(breast)-371.7(cancer)-368.3(survivors)-366.7(increases,)]TJ
7.3823 0 0 6.5614 289.644 708.2076 Tm
(1,2)Tj
9.843 0 0 9.843 78.5197 692.9006 Tm
[(due)-378.8(to)-388.2(early)-382.3(diagnosis)-385.3(and)-384.6(better)-389.3(treatments,)-388(more)-381.1(at-)]TJ
-1.9065 -1.1116 TD
[(tention)-256.9(needs)-249.5(to)-250(be)-251(paid)-253.4(to)-250(the)-246.5(impact)-252.3(of)-255.6(cancer)-253.1(treatment)-251.1(on)]TJ
0 -1.1174 TD
[(both)-211.9(short-)-208.1(and)-211.8(long-term)-214.1(quality)-210.8(of)-209.5(life)-213.1(of)-209.5(women.)-208(Fatigue)-211.7(is)]TJ
0 -1.1116 TD
[(one)-200.3(of)-198(the)-194.7(most)-195.6(frequently)-203.6(reported)-201.3(symptoms)-195.3(among)-198(women)]TJ
T*
[(with)-489.3(breast)-486.9(cancer)-489.3(undergoing)-490.3(adjuvant)-489.5(treatment.)]TJ
7.3823 0 0 6.5614 269.4613 653.4423 Tm
(3,4)Tj
9.843 0 0 9.843 283.5212 649.077 Tm
(The)Tj
-22.7336 -1.1174 TD
[(National)-484.7(Comprehensive)-486.5(Cancer)-489.2(Network)-483(denes)-480.9(cancer-)]TJ
0 -1.1116 TD
[(related)-270.6(fatigue)-269.4(as)-268.1()50.8()0(a)-268.3(persistent,)-270.2(subjective)-273.9(sense)-266.6(of)-267.1(tiredness)]TJ
T*
[(related)-431.9(to)-428.5(cancer)-431.7(or)-428.4(cancer)-431.7(treatments)-430.6(that)-426.3(interferes)-434.9(with)]TJ
T*
[(usual)-237(functioning.)45.2()]TJ
7.3823 0 0 6.5614 136.97 609.6188 Tm
(5)Tj
9.843 0 0 9.843 142.9795 605.2534 Tm
[(Women)-234.8(with)-235.9(breast)-239.2(cancer)-235.9(may)-236.1(already)]TJ
-8.4552 -1.1174 TD
[(experience)-287.6(fatigue)-281(before)-279.6(start)-283.2(of)-278.6(treatment.)]TJ
7.3823 0 0 6.5614 234.1983 598.6203 Tm
(3)Tj
9.843 0 0 9.843 240.6046 594.2549 Tm
(Cancer-related)Tj
-18.3735 -1.1116 TD
[(fatigue)-459.5(during)-456(initial)-458.8(treatment)-458.5(may)-455(occur)-457.1(in)-457.3(as)-452.4(many)-456.1(as)]TJ
T*
[(60%90%)-286.3(of)-278.6(women)-279.5(with)-282(breast)-285.3(cancer.)]TJ
7.3823 0 0 6.5614 221.2157 576.7368 Tm
(3)Tj
9.843 0 0 9.843 69.7323 561.3731 Tm
-.0158 Tc
[(Several)-587.2(c)-.8(ross-section)-15.8(a)9.6(l)-581.5(s).6(tudies)]TJ
7.3823 0 0 6.5614 192.3023 565.7952 Tm
-.0162 Tc
[(6)7.7(8)]TJ
9.843 0 0 9.843 208.6866 561.3731 Tm
[(and)-581.6(l)0(ongitudin)-16.1(a)9.3(l)-581.8(s).3(tud-)]TJ
-15.1307 -1.1116 TD
-.0156 Tc
(ies)Tj
7.3823 0 0 6.5614 70.2992 554.7967 Tm
-.0228 Tc
(9,10)Tj
9.843 0 0 9.843 88.3275 550.4313 Tm
-.0157 Tc
[(have)-582.4(reported)-581.2(greater)-581.2(f)-15.7(a)9.8(tigue)-582.4(among)-581.2(breast)-581.4(cancer)]TJ
-2.9029 -1.1116 TD
[(s)-15.8(u)11(rvivors)-442.9(who)-448.9(r).4(eceived)-443.1(c)-.8(hemother)-15.8(a)9.7(p).4(y)-443.1(c)-.8(ompared)-443.1(w)-.5(ith)-448.9(those)]TJ
0 -1.1174 TD
[(who)-241.5(r).4(eceived)-235.8(n).4(o)-241.5(a)-.8(djuvant)-235.9(chemotherapy)-15.8(.)-221.9(I)-15.8(n)-225.3(addition)-235.8(t)-15.8(o)-225.5(f).4(atigue)]TJ
0 -1.1116 TD
[(ari)-15.7(s)11(ing)-281.7(a)-.7(s)-275.8(a)-282.9(conseq)-15.7(u)10.9(e)-.7(nce)-277.1(o).5(f)-281.7(t).4(he)-282.9(cancer)-281.7(itself)-281.7(a)-.7(nd)-281.7(the)-282.9(t).4(reatment)]TJ
T*
[(women)-500.7(receive,)-497.3(p).4(sychological)-495.1(d)-15.8(i)10.7(stress,)-497.3(such)-495(as)-500.5(depression,)]TJ
T*
[(s)-15.8(o)11(mat)-15.8(i)10.5(zation,)-457(anxiety,)-457(and)-454.6(s)-15.8(l)10.9(eep)-454.6(disturban)-15.8(c)9.6(es)-454.4(can)-454.6(als)-15.8(o)-444(con-)]TJ
0 -1.1174 TD
[(tr)-15.8(i)10.7(bute)-438.5(t).3(o)-443.1(f).4(atigue)-438.5(dur)-15.8(i)10.7(n).4(g)-437.4(cancer)-443.1(treatment.)]TJ
7.3823 0 0 6.5614 227.9054 489.033 Tm
-.0162 Tc
(11)Tj
9.843 0 0 9.843 239.3574 484.6676 Tm
-.0157 Tc
(Chemotherapy-)Tj
-18.2467 -1.1116 TD
-.0159 Tc
[(rel)-15.9(a)9.4(ted)-518.1(f).3(atigue)-525(does)-517.9(not)-524(diminish)-518.1(over)-523.8(a)-519.3(3-year)-523.8(follow-up)]TJ
T*
[(per)-16(i)10.5(od,)]TJ
7.3823 0 0 6.5614 86.3433 467.1495 Tm
-.0162 Tc
(12)Tj
9.843 0 0 9.843 96.7181 462.7841 Tm
-.0157 Tc
[(and)-333.6(can)-333.6(last)-333.7(up)-333.6(to)-333.6(10)-333.6(years)-333.4(a)-.7(fter)-333.5(treatment.)]TJ
7.3823 0 0 6.5614 265.2661 467.1495 Tm
-.0239 Tc
(13)Tj
9.843 0 0 9.843 69.7323 451.7857 Tm
0 Tc
[(Persistent)-387.5(fatigue)-390.4(has)-384.4(a)-388.2(negative)-386.9(impact)-390.6(on)-382.3(daily)-387.1(activi-)]TJ
-1.0137 -1.1116 TD
[(ties,)-423.8(social)-423.7(relationships,)-423.4(and)-419.2(work,)-423.4(and)-419.2(causes)-424.4(signicant)]TJ
T*
[(impairment)-240.8(in)-238.5(the)-240.7(overall)-240.7(quality)-239.6(of)-232.6(life)-241.9(among)-238.3(breast)-239.2(cancer)]TJ
0 -1.1174 TD
(survivors.)Tj
7.3823 0 0 6.5614 98.8724 423.3259 Tm
(6,14,15)Tj
9.843 0 0 9.843 124.9511 418.9038 Tm
[(It)-399.7(is)-393.8(therefore)-405.1(of)-399.6(utmost)-399.6(importance)-401.9(to)-394(in-)]TJ
-6.6237 -1.1116 TD
[(vestigate)-347.7(effective)-348.8(strategies)-348.5(that)-345.6(can)-345.4(prevent)-350(or)-342(reduce)-344.1(the)]TJ
T*
[(prolonged)-339.5(impact)-333(on)-336.3(fatigue)-332.8(in)-336.4(breast)-337.1(cancer)-333.8(survivors.)]TJ
1.0137 -1.1174 TD
[(Despite)-183.8(the)-183.1(high)-183.1(prevalence)-184(of)-180.7(cancer-related)-190.8(fatigue,)-186.5(there)]TJ
-1.0137 -1.1116 TD
[(is)-186.4(limited)-183.4(evidence)-186.4(for)-181.8(interventions)-184(to)-186.6(manage)-184.1(this)-183(symptom.)]TJ
T*
[(A)-243.9(Cochrane)-243.7(review)-246(concluded)-243.9(that)-242(there)-244.1(is)-238.3(no)-244.1(solid)-236(evide)-8(nce)]TJ
T*
[(for)-297(the)-298.3(effectiveness)-296.4(of)-295.9(psychosocial)-298.8(interventions)-299.2(in)-296.1(reduc-)]TJ
0 -1.1174 TD
[(ing)-251.1(fatigue)-252.2(during)-254.4(cancer)-253.1(treatment,)-254.6(due)-252.1(to)-244.2(the)-252.3(heterogeneity)]TJ
0 -1.1116 TD
[(of)-399.6(the)-402(published)-402.8(studies.)]TJ
7.3823 0 0 6.5614 160.0441 335.6219 Tm
(16)Tj
9.843 0 0 9.843 171.3826 331.2566 Tm
[(Although)-401.6(there)-399.6(is)-399.5(growing)-406.1(evi-)]TJ
-11.3409 -1.1116 TD
[(dence)-233.6(that)-230.5(physical)-230.1(exercise)-232.2(has)-228.9(positive)-229(effects)-229.9(on)-226.8(fatigue,)]TJ
7.3823 0 0 6.5614 291.4582 324.6802 Tm
(17)Tj
9.843 0 0 9.843 59.7543 309.3164 Tm
[(cancer)-235.9(survivors)-228.5(are)-230.2(often)-231.4(unable)-227.9(to)-227(exercise)-232.2(because)-236.8(of)-226.8(their)]TJ
T*
[(severe)-401.5(fatigue)-396.2(condition)-397.4(itself.)]TJ
7.3823 0 0 6.5614 183.685 302.7401 Tm
(18)Tj
9.843 0 0 9.843 194.9669 298.3748 Tm
[(Therefore,)-398.1(yoga)-397.2(was)-391(pro-)]TJ
-13.7369 -1.1116 TD
[(posed)-162(as)-164.4(a)-163.5(possible)-159.6(promising)-166.7(intervention)-160(to)-163.6(reduce)-165.6(fatigue)-160(in)]TJ
0 -1.1174 TD
[(women)-273.7(with)-270.5(breast)-268(cancer,)-273.8(since)-267(it)-273.2(involves)-269.2(soft)-269.3(movements)]TJ
0 -1.1116 TD
[(to)-192.4(develop)-194.5(strength,)-192(exibility,)-194.7(and)-188.8(relaxation)-199.2(of)-192.2(the)-188.9(body)-188.7(and)]TJ
T*
(mind.)Tj
7.3823 0 0 6.5614 82.5448 258.9165 Tm
(19)Tj
9.843 0 0 9.843 93.3165 254.5511 Tm
[(Cramer)-351(et)-349.1(al.)]TJ
7.3823 0 0 6.5614 146.6078 258.9165 Tm
(20)Tj
9.843 0 0 9.843 157.3795 254.5511 Tm
[(conducted)-353.4(a)-342.1(systematic)-355.6(review)-344(and)]TJ
-9.9182 -1.1116 TD
[(reported)-379.8(that)-368.7(yoga,)-377.6(either)-372(during)-375.3(or)-370.8(after)-376.5(cancer)-374.1(treatment,)]TJ
0 -1.1174 TD
[(may)-328.2(have)-329.3(benecial)-331.5(effects)-327.9(on)-330.5(fatigue)-327(in)-324.9(breast)-331.4(cancer)-328(sur-)]TJ
0 -1.1116 TD
[(vivors,)-205.8(but)-205(that)-201.7(risk)-205.9(of)-203.8(publication)-205(bias)-201.3(could)-202.6(not)-205(be)-204.9(ruled)-202.6(out.)]TJ
1.0137 -1.1116 TD
[(At)-222.1(the)-217.7(initiation)-220.3(of)-221(the)-217.7(current)-223.2(study,)-216.2(only)-223.4(two)-217.4(pilot)-219(studies)]TJ
-1.0137 -1.1174 TD
[(were)-295.6(published)-299.1(that)-293.8(reported)-293.4(positive)-298.2(effects)-293.3(of)-295.9(yoga)-293.5(during)]TJ
0 -1.1116 TD
[(chemotherapy)-330.2(on)-324.7(fatigue)-321.3(in)-324.9(women)-325.6(with)-322.3(breast)-325.6(cancer.)-325.7(Re-)]TJ
T*
[(duction)-187.7(of)-186.5(fatigue)-183.1(was)-189.5(observed)-189.5(in)-180.9(a)-186.6(small)-186.5(single-arm)-187.4(study)-184(in)]TJ
0 -1.1174 TD
[(women)-302.5(with)-305(breast)-302.6(or)-301.7(ovarian)-303.9(cancer.)]TJ
7.3823 0 0 6.5614 210.8409 171.2692 Tm
(21)Tj
9.843 0 0 9.843 221.159 166.8472 Tm
[(Another)-303.6(pilot)-305.4(study)]TJ
-16.3979 -1.1116 TD
[(demonstrated)-179.2(a)-175(signicant)-174.7(reduction)-179.5(in)-169.4(fatigue)-177.3(in)-175.1(women)-175.8(with)]TJ
T*
[(breast)-463.9(cancer,)-463.9(but)-458.5(only)-459.5(upon)-459.4(within-group)-463.7(analysis)-466(\(yoga)]TJ
0 -1.1174 TD
[(group\))-329.1(and)-327(not)-326(in)-330.6(between-group)-329.8(analysis)-327.8(\(yoga)-329.2(vs.)-328(control)]TJ
0 -1.1116 TD
(group\).)Tj
7.3823 0 0 6.5614 88.4976 127.3889 Tm
(22)Tj
9.843 0 0 9.843 101.5937 123.0236 Tm
[(Accordingly,)-583.4(although)-586.2(there)-583.9(is)-578.1(some)-582.6(evidence)]TJ
-4.2507 -1.1116 TD
[(supporting)-212.6(the)-211.9(benecial)-216.3(effects)-212.7(of)-215.3(yoga)-207.2(on)-215.3(fatigue)-211.8(in)-209.7(women)]TJ
T*
[(with)-552.7(breast)-556(cancer)-552.6(during)-548.1(chemotherapy,)-558.3(additional)-555.3(ran-)]TJ
0 -1.1174 TD
[(domized)-224.5(controlled)-226.8(trials)-221(\(RCTs)-8.5(\))-219.9(with)-224.4(yoga)-218.7(interventions)-224.3(are)]TJ
0 -1.1116 TD
[(needed)-263.5(to)-261.5(conrm)-262.2(its)-262.5(effectiveness.)]TJ
1.0137 -1.1116 TD
[(The)-345.5(present)-349.8(study)-345.3(was)-345(initiated)-346.9(to)-347.9(investigate)-350(the)-344.4(effects)]TJ
-1.0137 -1.1174 TD
[(of)-520.5(a)-514.9(yoga)-512.4(program)-522.6(during)-513.6(chemotherapy)-520.3(on)-514.8(fatigue)-517.1(and)]TJ
25.5097 67.8551 TD
[(quality)-343.3(of)-347.8(life)-345.6(in)-342.1(women)-348.6(with)-345.4(breast)-348.7(cancer)-351.1(when)-346.3(added)-347.7(to)]TJ
0 -1.1174 TD
[(standard)-356.6(care)-359.2(\(SC\))-356.6(compared)-359.1(with)-356.9(SC)-354.4(only.)-353.5(To)-360.5(the)-355.9(best)-356.8(of)]TJ
0 -1.1116 TD
[(our)-308.5(knowledge,)-316.2(this)-309.7(is)-313.2(the)-309.9(rst)-309.4(RCT)-311.8(in)-313.3(the)-309.9(Netherlands)-316(that)]TJ
T*
[(investigated)-270.5(the)-275.3(effectiveness)-273.4(of)-272.9(yoga)-270.5(on)-267.1(fatigue)-269.4(and)-275.2(quality)]TJ
T*
[(of)-330.5(life)-334.1(in)-336.4(women)-337.1(with)-333.8(breast)-337.1(cancer.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 655.7101 Tm
[(Materials)-337.3(and)-335.3(Methods)]TJ
/F13 1 Tf
0 -1.8336 TD
[(Study)-332.3(design)-336.6(and)-329.4(participants)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 622.8282 Tm
[(A)-543.4(multicenter)-547.2(pragmatic,)-553.9(randomized)-545.7(controlled)-549.4(study)]TJ
-1.0137 -1.1116 TD
[(with)-264.7(two)-269.2(parallel)-271.8(groups)-271.3(was)-270.1(performed)-266.8(in)-267.3(three)-272.9(hospitals)-270.3(in)]TJ
T*
[(the)-499.9(Netherlands:)-507.3(St)-497.5(Jansdal)-505.1(Hospital)-500.6(\(Harderwijk\),)-504.7(Alex-)]TJ
0 -1.1174 TD
[(ander)-658.6(Monro)-657.2(Hospital)-661.9(\(Bilthoven\),)-663.2(and)-655.3(Flevo)-663.2(Hospital)]TJ
0 -1.1116 TD
[(\(Almere\).)-293.2(Women)-292.4(between)-294.4(18)-284.4(and)-292.4(70)-290.2(years)-289.8(with)-293.5(stage)-290(IIII)]TJ
T*
[(breast)-394.7(cancer)-391.4(who)-390.1(were)-393.5(scheduled)-393.5(for)-394.9(\(neo\))-392.5(adjuvant)-391.5(che-)]TJ
0 -1.1174 TD
[(motherapy)-370.7(were)-370.4(eligible)-368.8(for)-371.9(the)-367.5(study.)-371.7(They)-369.6(had)-367.3(to)-365.2(under-)]TJ
0 -1.1116 TD
[(stand)-496.2(and)-494(speak)-497.2(the)-499.9(Dutch)-497.2(language)-496.3(and)-499.8(have)-496.3(access)-500.5(to)]TJ
T*
[(phone)-323.5(and)-321.2(internet.)-320.2(Written)-328.3(informed)-322.3(consent)-326.8(was)-321.9(obtained)]TJ
0 -1.1174 TD
[(before)-342.9(inclusion)-345.3(in)-347.9(to)-342.1(the)-344.4(study.)-342.9(Women)-350(who)-344(had)-344.3(received)]TJ
0 -1.1116 TD
[(previous)-326.7(treatment)-326(with)-328.1(cytostatics)-326.8(were)-330.1(excluded)-323.5(from)-328.1(the)]TJ
T*
[(study.)-314.1(Other)-312.9(exclusion)-317.6(criteria)-317.9(were:)-319.8(presence)-318.5(of)-313.2(metastasis)]TJ
0 -1.1174 TD
[(or)-272.9(other)-277.5(malignancies,)-276.2(irresectable)-284.1(tumors,)-276.1(deafness,)-274.5(serious)]TJ
0 -1.1116 TD
[(psychiatric)-372.9(or)-365(cognitive)-369.7(problems,)-371.6(or)-365(participating)-375.5(in)-365.2(other)]TJ
T*
[(yoga)-333.9(or)-330.5(stress-reduction)-343.4(programs)-333.5(at)-337.6(the)-332.9(time.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 310.8472 443.792 Tm
(Intervention)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 427.3511 Tm
[(Women)-303.9(were)-307.1(randomized)-315.3(to)-301.8(either)-308.7(SC)-308.3(\(control)-309.7(group\))-306.1(or)]TJ
-1.0137 -1.1116 TD
[(SC)-533(plus)-540(the)-534.5(yoga)-541.2(program.)-537.6(SC)-538.7(was)-535(provided)-540(according)]TJ
T*
[(to)-440.1(the)-448.1(hospital)-442.2(guidelines.)-449(Th)19.6(i)16.1(s)-432.9(wa)24.6(s)-432.9(a)0(n)-423.8(i)16(nd)20.8(iv)26.5(id)20.7(ua)25.4(l)-433.2(m)0(i)25.2(x)0(t)20.7(u)0(r)26.6(e)]TJ
0 -1.1174 TD
-.0241 Tc
[(o)-24.1(f)-579.2(\()-24.1(n)-3.2(e)-9.1(o)-24.1(\))-585(a)-24.1(dj)-24.1(uv)-24.1(an)-24.1(t)-585.1(c)-9.1(h)-24.1(e)-4.4(m)-9.1(o)-24.1(th)-24.1(er)-24.1(a)-4.4(p)-24.1(y,)-597.7(s)-7.7(u)-24.1(rg)-24.1(er)-24.1(y)-585(\()-24.1(ma)-24.1(s)-4.2(t)-24.1(ec)-24.1(t)-4.6(o)-7.9(m)-24.1(y)-586.2(o)-7.9(r)]TJ
0 -1.1116 TD
0 Tc
[(lu)26.5(mp)19.6(e)15(c)0(t)19.6(o)0(m)25.4(y)0(\))20.9(,)-222.3(ra)19.7(d)16.2(i)0(o)20.7(t)0(h)26.5(e)0(r)19.7(a)0(p)25.4(y)0(,)-211.9(a)0(n)19.7(d)0(/)26.5(o)0(r)-215.3(i)0(m)25.2(m)0(u)19.6(n)0(o)26.6(t)0(h)20.7(e)15(ra)19.7(py)26.6(,)-228.1(a)0(s)-216.3(w)15.3(el)19.5(l)-225.9(a)15(s)]TJ
T*
[(su)26.8(pp)20.8(or)26.6(t)-444.7(f)0(r)20.9(o)0(m)-435.4(o)16.2(nc)19.7(ol)26.5(og)20.8(y)-444.6(n)0(u)26.6(r)0(s)21.1(e)0(s)-435.1(t)0(h)26.5(r)0(o)20.9(u)0(g)26.6(h)0(o)20.8(u)0(t)-434.3(t)16.1(he)-435.3(pr)20.9(o)16.2(c)0(e)18.5(s)0(s)27(.)-446.9(Th)25.4(e)]TJ
T*
[(yo)26.6(ga)-343.2(p)16.2(r)0(o)20.9(g)0(r)26.6(a)0(m)-344.4(c)15(on)20.8(si)26.7(st)20.9(ed)-337.4(of)-342(w)15.3(e)0(e)18.5(k)16.2(ly)-342.2(se)25.6(ss)21.2(io)20.7(n)16.2(s)-352.2(of)-336.2(75)-146.2(m)15(i)0(n)-342.1(a)15(t)-352.6(t)0(h)20.7(e)]TJ
0 -1.1174 TD
[(ho)26.6(sp)21(it)26.3(al)-280(o)16.2(v)0(e)19.7(r)-289.1(a)-284.5(p)0(e)19.7(r)16.2(io)20.7(d)-283.3(o)0(f)-278.6(1)0(2)-272.9(w)0(e)18.8(e)15(ks)21(.)-285.6(W)0(o)24.3(m)0(e)18.4(n)-283.3(en)19.7(t)16(e)0(r)19.7(e)0(d)-274.1(t)0(h)20.7(e)-284.5(yo)20.8(ga)]TJ
0 -1.1116 TD
[(pr)26.6(og)20.8(ra)25.5(m)-440.1(1)0()26.6(2)-438.8(we)24.6(ek)19.7(s)-438.6(b)16.2(ef)19.7(or)26.6(e)-440(t)0(h)26.5(e)-440(st)20.9(a)15(r)0(t)-428.5(o)0(f)-422.6(c)0(h)19.7(e)15(mo)19.6(t)16.1(h)0(e)19.7(r)0(a)25.5(p)0(y)20.8(.)-435.4(Th)25.4(e)]TJ
T*
[(pr)26.6(og)20.8(ra)25.5(m)-313.3(w)15.3(as)-302.7(b)16.2(a)0(s)19.9(e)0(d)-297.1(o)0(n)-295.9(D)0(r)20(u)-306.4(Yo)20(ga)]TJ
7.3823 0 0 6.5614 441.4109 333.1275 Tm
-.0162 Tc
(23)Tj
9.843 0 0 9.843 451.729 328.7621 Tm
0 Tc
[(an)19.7(d)-306.4(s)0(p)21(e)0(c)24.3(i)0()20.9(c)0(a)24.3(l)0(l)20.6(y)-306.4(de)19.7(si)26.7(gn)20.8(e)15(d)]TJ
-14.3129 -1.1174 TD
[(fo)26.6(r)-312.1(w)0(o)20(m)15(en)-302.9(w)15.3(i)0(t)20.6(h)-312.1(b)16.2(r)0(e)19.7(a)0(s)19.9(t)-306.5(ca)18.5(n)16.2(c)0(e)18.5(r)-312.1(t)16.1(o)-312.1(re)19.7(d)16.2(u)0(c)19.7(e)-313.3(f)16.2(a)0(t)19.6(i)0(g)26.5(u)0(e)-302.9(a)0(n)25.4(d)-312.1(im)25.2(pr)20.9(ov)20.8(e)]TJ
0 -1.1116 TD
[(qu)26.6(al)19.5(i)16.1(t)0(y)-284.5(o)0(f)-284.4(l)16.1(if)20.7(e.)-282.2(Dr)20(u)-289.1(Y)0(o)20(g)0(a)-279.8(i)0(s)-284.4(a)-296(s)16.4(t)0(y)20.7(l)0(e)-280(o)0(f)-284.4(y)0(o)20.8(g)16.2(a)-296(t)0(h)20.7(a)15(t)-295(i)0(s)-284.4(c)15(om)19.6(m)15(o)0(n)20.8(l)0(y)]TJ
T*
[(pr)26.6(ac)18.5(t)16.1(i)0(c)19.5(e)0(d)-302.9(i)0(n)-307.6(t)16(he)-308.6(N)15.3(e)0(t)19.6(h)0(e)25.4(r)0(l)20.7(a)0(n)25.4(d)0(s)-307.3(a)0(s)-302.7(w)0(e)18.8(l)16.1(l)-318(a)0(s)-302.7(t)0(h)20.7(e)-319(U)15.3(n)0(i)20.7(t)0(e)25.3(d)-317.9(Ki)25.6(ng)20.8(do)26.6(m.)]TJ
0 -1.1174 TD
[(T)15(h)0(e)-314.4(c)15(on)20.8(te)25.3(nt)-313.4(o)16.2(f)-323.6(th)20.7(e)-319(y)0(o)20.8(g)16.2(a)-324.8(p)0(r)26.6(o)0(g)20.8(r)0(a)25.5(m)-324.9(i)16(s)-323.4(su)21(m)15(m)0(a)18.5(r)16.2(iz)19.5(ed)-308.6(in)-307.6(Ta)18.5(b)16.2(l)0(e)-314.5(1)0(.)]TJ
1.0137 -1.1116 TD
[(In)-278.6(addition)-286.8(to)-284.5(the)-286.8(weekly)-286.4(sessions,)-283.5(women)-285.2(were)-289.8(provided)]TJ
-1.0137 -1.1116 TD
[(with)-466.3(a)-468.8(C)0(D)-470.6(o)0(r)-468.7(MP3)-464.8(download)-471.8(with)-466.3(20)-169.2(min)-465.4(breathing)-473.3(and)]TJ
T*
[(relaxation)-377.7(exercises)-382.9(to)-376.7(practice)-382.3(at)-377.9(home.)-373.1(Women)-378.8(were)-382(en-)]TJ
0 -1.1174 TD
[(couraged)-524.9(to)-520.7(practice)-532.1(at)-521.9(home)-525.2(daily)-525.3(with)-523.9(a)-520.6(minimum)-530(of)]TJ
0 -1.1116 TD
[(5)-168.1(min.)-399.8(The)-403.1(yoga)-403(program)-407.5(was)-402.6(developed)-405.2(and)-401.9(provided)-407.5(by)]TJ
T*
[(yoga)-414.5(instructors)-416.4(of)-416.9(the)-419.3(Clyms)-416.6(Institute)-414.5(in)-417(Harderwijk,)-421.9(the)]TJ
0 -1.1174 TD
[(Netherlands.)-279.1(The)-282.1(instructors)-278.2(were)-284(certied)-277.3(in)-278.8(Dru)-280.6(Yoga)-277.1(and)]TJ
0 -1.1116 TD
[(had)-275.2(more)-271.7(than)-276.4(5)-271.8(years)-272.6(of)-272.9(experience)-281.9(in)-273(working)-273.6(with)-270.5(cancer)]TJ
T*
[(patients.)-256.7(Women)-257.8(in)-255.8(the)-258(SC)-256.5(group)-258.9(were)-255.2(offered)-257.6(to)-255.8(participate)]TJ
0 -1.1174 TD
[(in)-330.6(the)-338.7(yoga)-333.9(program)-332.6(after)-336.2(the)-332.9(study.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 310.8472 149.726 Tm
(Randomization)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 133.285 Tm
[(Women)-269.4(were)-272.5(assigned)-270.1(to)-273(one)-269.4(of)-267.1(the)-269.5(following)-276.1(four)-269.3(strata,)]TJ
-1.0137 -1.1116 TD
[(mastectomy,)-561.9(lumpectomy,)-560.9(neoad)-7.8(juvant)-555.2(chem)-8(otherapy,)-561.8(or)]TJ
0 -1.1174 TD
[(adjuvant)-316.7(chemotherapy,)-322.1(taking)-319.1(into)-321.4(account)-322.4(prognostic)-317.5(fac-)]TJ
0 -1.1116 TD
[(tors)-419(which)-428.1(may)-420.4(interfere)-428.3(with)-420.2(therapy)-424.8(outcome.)]TJ
7.3823 0 0 6.5614 508.8188 104.7685 Tm
[(12,1)-8.6(6)]TJ
9.843 0 0 9.843 529.6251 100.4031 Tm
(They)Tj
-22.2267 -1.1116 TD
[(were)-226.4(subsequently)-222.8(randomized)-228.9(using)-224.3(separate)-226.5(randomization)]TJ
0 -1.1174 TD
[(lists)-258.9(for)-262.4(each)-267.1(study)-264.6(center,)-261.3(as)-262.4(generated)-268.1(by)-261.4(the)-263.8(computerized)]TJ
0 -1.1116 TD
[(Random)-298(Allocation)-297(Software)-299.9(Program)-297.9(with)-299.3(a)-296(random)-297(block)]TJ
T*
[(size)-167.9(of)-169.2(10)-169.2(to)-163.6(guarantee)-175.9(balanced)-169.1(allocation.)-174(The)-166.9(study)-172.5(monitor)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(TRIAL)-336.6(OF)-337.5(YOGA)-329.3(ON)-334.6(FATIGUE)-337.6(IN)-335.1(BREAST)-338.7(CANCER)-28130(943)]TJ
ET
endstream
endobj
53 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 363.6283 Tm
0 0 0 rg
0 Tc
0 Tw
[(was)-252.8(blinded)-251(for)-256.7(allocation)-251.2(sequence)-255.2(and)-252.1(assigned)-258.5(subjects)-252.9(to)]TJ
0 -1.1116 TD
[(the)-263.8(groups.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 62.022 330.633 Tm
[(Outcome)-337.1(measures)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 314.192 Tm
-.0157 Tc
[(Outc)-15.7(o)9.7(mes)-321.9(w)-15.7(e)8.9(re)-323.2(me)-15.7(a)8.6(s).7(ur)-15.7(e)9.8(d)-322.1(at)-322.2(b)-15.7(a)9.7(seli)-15.7(n)10.8(e)-323.2(\(T0)-15.7(\))10.9(,)-324.4(3)-322.1(mont)-15.7(h)10.8(s)-321.9(\()-15.7(T)9.7(1\),)]TJ
-1.0137 -1.1116 TD
-.0159 Tc
[(and)-437.5(a)-.9(t)-431.8(6)-431.7(m)-15.9(o)9.5(nths)-437.3(\(T2\))-437.4(foll)-15.9(o)10.6(w-u)-15.9(p)10.7(.)-434(P).4(rim)-15.9(a)8.3(ry)-431.7(ou)-15.9(t)10.6(c)-.9(ome)-438.6(w)-.6(as)-431.5(t)-15.9(h)10.6(e)]TJ
T*
-.0158 Tc
[(gen)-15.8(e)9.6(ral)-379.9(f)-15.8(a)9.7(tigu)-15.8(e)-370.5(scal)-15.8(e)-364.9(a)-15.8(t)-370.6(T)-.8(1,)-382.1(measur)-15.8(e)9.7(d)-379.8(by)-379.8(th)-15.8(e)-364.7(2)-15.8(0)10.8(-).4(it)-15.8(e)9.5(m)-381(Multi)-15.8(-)]TJ
0 -1.1174 TD
-.016 Tc
[(di)-16(m)9.2(e)-1(nsi)-16(o)10.5(nal)-426.2(F).3(ati)-16(g)10.5(ue)-427.2(Inven)-16(t)10.5(ory)-426(\()-86.2(M)-.7(FI\))-16(,)-412.2(whic)-16(h)-411(a)-1(l)-16(s)10.7(o)-420.3(m)-1(e)-16(a)8.3(sur)-16(e)9.5(d)]TJ
0 -1.1116 TD
-.0157 Tc
[(ph)-15.7(y)10.9(s).7(ic)-15.7(a)8.6(l)-201.2(and)-201.1(men)-15.7(t)10.8(a)-.7(l)-201.2(f).5(at)-15.7(i)10.6(gue)-15.7(.)]TJ
7.3823 0 0 6.5614 168.3212 274.7338 Tm
-.0162 Tc
(24)Tj
9.843 0 0 9.843 177.3921 270.3684 Tm
[(A)-16.1(n)9.6(oth)-16.1(e)9.3(r)-201.5(m)-1.1(ore)-202.7(qu)-16.1(a)9.3(lit)-16.1(a)9.2(tive)-202.7(f)-16.1(a)9.4(tig)-16.1(u)10.5(e)]TJ
-11.721 -1.1116 TD
0 Tc
[(m)15(e)15(a)0(s)25.6(u)16.2(r)16.2(e)0(m)24.2(e)15(n)16.2(t)-208.6(us)26.8(e)15(d)-214.2(w)15.3(a)15(s)-214(t)16.1(h)16.2(e)-209.6(18)26.6(-)16.2(i)16.1(te)25.3(m)-209.7(F)16.3(at)25.3(i)16.1(g)16.2(ue)-199.2(Q)15.3(u)16.2(al)25.3(i)16.1(t)16.1(y)-214.2(L)15(i)16.1(s)16.4(t)-214.3(\()16.2(F)16.3(QL)24.5(\))]TJ
T*
-.0157 Tc
[(as)-15.7(s)11.3(e)-.7(ss)-15.7(i)11(n).5(g)-443(w)-.4(o)-15.7(m)9.7(ens)-442.8(p)-15.7(e)9.7(rcep)-15.7(t)10.8(i).4(on)-443(an)-15.7(d)-432.6(a)-.7(ppr)-15.7(a)9.8(i).4(sal)-443.1(o)-15.7(f)-432.6(e)-.7(xper)-15.7(i)10.8(enc)-15.7(e)8.6(d)]TJ
0 -1.1174 TD
-.0162 Tc
[(fa)-16.2(t)9.1(i)-.1(gue)-16.2(.)]TJ
7.3823 0 0 6.5614 90.7653 241.8519 Tm
(25)Tj
9.843 0 0 9.843 104.485 237.4866 Tm
-.0155 Tc
[(Ano)-15.5(t)11(her)-673.2(s).9(econ)-15.5(d)11.1(ary)-673.2(outc)-15.5(o)9.9(me)-668.6(was)-673(h).7(eal)-15.5(t)10.8(h-r)-15.5(e)10(l).6(at)-15.5(e)9.8(d)]TJ
-4.314 -1.1116 TD
-.016 Tc
[(qu)-16(a)9.4(lity)-466.4(of)-460.6(l)-16(i)10.3(fe)-461.8(m)-16(e)8.2(asur)-16(e)9.5(d)-460.6(us)-16(i)10.7(n).2(g)-466.4(t).1(he)-461.8(3)-16(0)10.6(-it)-16(e)9.3(m)-461.8(Q)-.7(ual)-16(i)10.3(ty)-466.4(of)-460.6(Li)-16(f)10.5(e)]TJ
T*
-.0155 Tc
[(Qu)-15.5(e)9.9(s).9(ti)-15.5(o)11(nnai)-15.5(r)11(e-C)-409.3(o).7(f)-402.5(t).6(h)-15.5(e)-393.2(Eur)-15.5(o)11.1(pean)-408.3(Orga)-15.5(n)9.9(i).6(zat)-15.5(i)10.8(o).7(n)-402.5(f)-15.5(o)11.1(r)-402.5(Re)-15.5(s)10.1(ear)-15.5(c)10(h)]TJ
0 -1.1174 TD
[(and)-166.3(T)-.5(r)-15.5(e)10(atmen)-15.5(t)-150.3(o)-15.5(f)-150.1(C)-.3(a)-15.5(n)9.9(cer)-166.3(\(EO)-15.5(R)9.2(TC-Q)-15.5(L)9(Q)-.2(-C-)-15.5(3)11.1(0\),)]TJ
7.3823 0 0 6.5614 241.9653 208.97 Tm
-.0162 Tc
(26)Tj
9.843 0 0 9.843 250.696 204.6047 Tm
-.0155 Tc
[(adju)-15.5(s)11.3(t).6(ed)-166.3(wi)-15.5(t)10.8(h)]TJ
-19.1683 -1.1116 TD
-.0157 Tc
[(th)-15.7(e)-525.9(2)-15.7(3)10.9(-).5(ite)-15.7(m)-527.1(b)-15.7(r)10.9(east)-541.1(c)-.7(a)-15.7(n)9.7(cer-)-15.7(s)11.1(pe)-15.7(c)8.6(i).4(c)-542.1(modu)-15.7(l)10.8(e)-.7(:)-541.1(E)-.7(ORTC)-542(QL)-15.7(Q)8.8(-)]TJ
T*
-.0152 Tc
[(BR2)-15.2(3)11.4(.)]TJ
7.3823 0 0 6.5614 86.7401 187.0866 Tm
-.0239 Tc
(27)Tj
9.843 0 0 9.843 95.5275 182.7212 Tm
-.0158 Tc
[(Oth)-15.8(e)9.6(r)-172.4(s)-15.8(e)9.8(c)-.8(ond)-15.8(a)9.6(r).4(y)-172.4(o)-15.8(u)10.8(t).3(come)-15.8(s)-163(w)-.5(er)-15.8(e)-163.1(p).4(sy)-15.8(c)9.6(hol)-15.8(o)10.7(g).4(ica)-15.8(l)-163.3(dis)-15.8(t)10.9(res)-15.8(s)]TJ
-3.404 -1.1174 TD
[(as)-218.2(meas)-15.7(u)11.1(r).5(ed)-218.4(by)-218.4(the)-219.5(14-it)-15.7(e)9.6(m)-213.9(H)-.4(o)-15.7(s)11.1(pit)-15.7(a)9.6(l)-212.8(A)-15.7(n)10(x).5(ie)-15.7(t)9.6(y)-212.6(De)-15.7(p)9.7(r).5(es)-15.7(s)11.3(i).4(on)-218.4(Sca)-15.7(l)9.6(e)]TJ
0 -1.1116 TD
-.0163 Tc
[(\(H)-16.3(A)8.6(D)-1(S\))-16.3(,)]TJ
7.3823 0 0 6.5614 96.6614 165.1464 Tm
(28)Tj
9.843 0 0 9.843 107.6598 160.7811 Tm
-.0157 Tc
[(the)-392.3(2).5(2)-15.7(-)10.9(item)-392.4(I)-15.7(m)9.7(p).5(act)-397.1(of)-391.1(Even)-15.7(t)10.8(s)-391(Sc)-15.7(a)8.6(l).4(e)-392.3(\().5(I)-15.7(E)9.7(S\),)]TJ
7.3823 0 0 6.5614 276.2078 165.1464 Tm
-.0162 Tc
(29)Tj
9.843 0 0 9.843 287.1495 160.7811 Tm
0 Tc
[(an)25.4(d)]TJ
-22.8718 -1.1116 TD
-.0155 Tc
[(tr)-15.5(e)10(a)-.5(tmen)-15.5(t)-300.1(e)-.5(x)-15.5(p)11.1(ecta)-15.5(t)9.8(ions)-315.9(meas)-15.5(u)11.3(r).7(ed)-316.1(by)-310.3(t)-15.5(h)11(e)-311.5(P)-15.5(a)10.1(r).7(ti)-15.5(c)9.8(i).6(pan)-15.5(t)11(s)-310.1(E)-.5(x)-15.5(p)11.1(ect)-15.5(a)9.8(-)]TJ
0 -1.1174 TD
-.016 Tc
[(ti)-16(o)10.5(n).2(s)-345.2(q)-16(u)10.6(e)-1(st)-16(i)10.3(onna)-16(i)9.3(r).2(e.)]TJ
7.3823 0 0 6.5614 137.4803 143.263 Tm
-.0162 Tc
(30)Tj
9.843 0 0 9.843 147.9685 138.8409 Tm
0 Tc
[(Ad)25.7(e)15(q)16.2(u)16.2(a)0(t)25.3(e)-330.6(r)16.2(e)15(li)26.3(e)15(f)-329.4(of)-319(f)16.2(a)15(ti)26.3(g)16.2(u)16.2(e)-330.6(\(y)26.6(e)15(s)16.4(/n)26.5(o)16.2(\))-329.4(an)25.4(d)]TJ
-8.7317 -1.1116 TD
-.0157 Tc
[(re)-15.7(t)9.6(urn)-350.9(to)-350.9(work)-350.9(wer)-15.7(e)-335.8(as)-15.7(s)11.3(e)-.7(s)-15.7(s)11.3(ed)-350.9(in)-345.1(s)-15.7(e)9.9(mis)-15.7(t)11(ruct)-15.7(u)10.8(red)-350.9(t).4(el)-15.7(e)9.6(pho)-15.7(n)10.9(e)-346.3(i)-15.7(n)10.8(-)]TJ
T*
-.0159 Tc
[(te)-15.9(r)9.6(v).3(iew)-305.8(c)-.9(a)-15.9(r)9.6(rie)-15.9(d)-290(o)-15.9(u)10.7(t)-305.1(b).3(y)-305(t).2(he)-306.1(re)-15.9(s)9.7(earc)-15.9(h)-295.7(phys)-15.9(i)10.8(c)-.9(ian)-15.9(.)-291.1(In)-305(ad)-15.9(d)10.7(itio)-15.9(n)10.7(,)-301.6(t)-15.9(h)10.6(e)]TJ
T*
0 Tc
[(o)16.2(c)15(cu)25.4(r)16.2(r)16.2(e)0(n)25.4(c)15(e)-244.2(o)0(f)-232.6(s)16.4(tu)26.5(d)16.2(y)16.2(-)0(r)26.7(e)15(l)16.1(a)15(te)25.3(d)-243(a)15(dv)26.6(e)15(r)16.2(se)-233.6(e)15(v)16.2(en)25.4(t)16.1(s)-242.8(wa)24.6(s)-242.8(m)15(on)26.6(i)16.1(t)16.1(o)0(r)26.6(e)15(d)16.2(.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 62.022 83.9622 Tm
[(Sample)-332.2(size)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 67.5212 Tm
[(Calculation)-460.7(of)-457.2(the)-459.6(sample)-459.4(size)-455.9(was)-460.2(powered)-460.1(to)-457.3(a)-457.3(21%)]TJ
-1.0137 -1.1116 TD
[(point)-403.2(difference)-413.1(between)-403.9(the)-407.8(control)-400.8(and)-407.6(yoga)-403(group)-402.9(with)]TJ
25.504 67.9242 TD
[(respect)-587.1(to)-578.3(the)-580.6(primary)-580.4(outcome)-581.6(of)-578.1(self-reported)-582.2(fatigue)]TJ
0 -1.1174 TD
[(\()-87.5(MFI:)-552.4(general)-552.7(fatigue\))-558.5(at)-550.7(3)-554(months)-555(follow-up.)-550.1(This)-552.7(as-)]TJ
0 -1.1116 TD
[(sumption)-436.3(was)-431.4(based)-428.1(on)-428.4(results)-434.9(from)-431.8(two)-430.5(previous)-430.3(studies)]TJ
T*
[(invest)-7.8(igating)-314.5(the)-315.6(effects)-316.3(of)-313.2(yoga)-316.6(on)-313.2(fatigue)-315.5(in)-313.3(breast)-314.1(cancer)]TJ
T*
(survivors.)Tj
7.3823 0 0 6.5614 352.1763 685.7006 Tm
(31,32)Tj
9.843 0 0 9.843 372.5857 681.3352 Tm
[(A)-382.1(sample)-384.5(size)-386.8(of)-382.3(43)-382.3(women)-383.2(per)-384.6(group)-385.6(pro-)]TJ
-6.0477 -1.1174 TD
[(vided)-317.8(80%)-309.6(power)-312.8(assuming)-316.2(a)-307.5(signicance)-316.2(level)-313.4(of)-313.2(0.05.)-309.7(To)]TJ
0 -1.1116 TD
[(control)-302.8(for)-297(an)-302.9(estimated)-302.8(20%)-298.1(dropout)-301.6(rate,)-298.2(the)-298.3(total)-300.8(number)]TJ
T*
[(of)-353.5(women)-348.6(required)-351(per)-350(group)-351.1(was)-350.7(calculated)-357(to)-347.9(be)-348.9(52,)-351.2(and)]TJ
0 -1.1174 TD
[(104)-337.4(women)-331.3(in)-336.4(total.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 313.0582 615.5148 Tm
[(Statistical)-342.4(analyses)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 599.0739 Tm
[(Ma)18.8(in)-370.9(st)20.9(at)19.5(is)20.9(ti)20.6(ca)12.8(l)-375.6(a)0(n)19.7(a)0(l)19.5(y)0(s)21(e)0(s)-371.8(w)0(e)18.8(r)0(e)-366.2(p)0(e)19.7(r)0(-)20.9(p)0(r)15.1(o)0(t)20.7(o)0(c)19.7(o)0(l)-365.2(\()0(P)21(P)0(\))-370.6(a)0(n)19.7(a)0(l)19.5(y)0(s)21(i)0(s)15.1(,)]TJ
-1.0137 -1.1116 TD
[(ba)13.9(se)19.9(d)-346.7(o)0(n)-336.3(o)0(b)20.8(s)0(e)19.9(r)0(v)15.1(e)0(d)-337.4(d)0(a)19.7(t)0(a)-337.6(f)0(r)20.9(o)0(m)-337.5(w)0(o)20(m)0(e)18.4(n)-346.7(wh)20(o)-346.7(w)0(e)18.8(r)0(e)-343.2(r)0(a)19.7(n)0(d)20.8(o)0(m)19.6(i)0(z)19.5(e)0(d)]TJ
T*
[(an)13.9(d)-381.2(f)0(o)15.1(l)0(l)20.6(o)0(w)20(e)0(d)19.7(-)0(u)20.9(p)-387(fo)20.9(r)-387(3)-387(a)0(n)19.7(d)-387(6)-387(m)0(o)19.6(n)0(t)20.7(h)0(s)-376.4(i)0(n)-376.7(t)0(h)20.7(e)-388.2(st)20.9(ud)20.8(y.)-378.9(Ba)18.6(se)19.9(li)20.6(ne)]TJ
0 -1.1174 TD
[(de)13.9(mo)19.6(gr)20.9(ap)19.7(hi)20.7(c)-353.6(a)0(n)19.7(d)-352.4(cl)19.6(in)20.7(ic)19.6(al)-343.3(ch)19.7(ar)19.7(ac)18.5(te)19.5(ri)15(st)20.9(ic)19.5(s)-352.2(w)0(e)18.8(r)0(e)-343.2(c)0(a)18.5(l)0(c)19.5(u)0(l)20.7(a)0(t)19.5(e)0(d)-343.2(u)0(s)21(-)]TJ
0 -1.1116 TD
[(in)15(g)]TJ
/F6 1 Tf
1.6818 0 TD
(t)Tj
/F5 1 Tf
.2707 0 TD
[(-t)15(es)19.9(ts)-411.1(fo)20.9(r)-421.5(c)0(o)19.7(n)0(t)20.7(i)0(n)20.7(u)0(o)20.8(u)0(s)-410.9(a)0(n)19.7(d)-421.6(or)20.9(di)20.7(na)13.9(l)-415.9(v)0(a)19.7(r)0(i)15(a)0(b)19.7(l)0(e)19.6(s)0(.)-407.5(C)0(h)19.8(i)0(-)15(s)0(q)21(u)0(a)19.7(r)0(e)]TJ
-1.9525 -1.1116 TD
[(te)13.8(st)20.9(s)-323.4(w)0(e)18.8(r)0(e)-314.4(u)0(s)21(e)0(d)-314.4(t)0(o)-313.4(c)0(o)19.7(m)0(p)19.6(a)0(r)14(e)-319(no)15.1(mi)19.5(na)19.7(l)-323.8(v)0(a)19.7(r)0(i)20.7(a)0(b)19.7(l)0(e)19.5(s)0(.)]TJ
1.0137 -1.1174 TD
[(Within-group)-493.9(analyses)-490.1(were)-497.1(performed)-491.4(to)-486.1(estimate)-497.5(the)]TJ
-1.0137 -1.1116 TD
[(effects)-397(of)-388.1(the)-390.5(intervention)-390.4(after)-393.8(3)-387(and)-390.4(6)-387(months)-393.7(compared)]TJ
T*
[(with)-356.9(baseline)-357.9(using)]TJ
/F6 1 Tf
8.3055 0 TD
(t)Tj
/F5 1 Tf
.2822 0 TD
[(-tests)-353.2(or)-353.5(MannWhit)-8.8(ney)]TJ
/F6 1 Tf
10.2984 0 TD
(U)Tj
/F5 1 Tf
1.0771 0 TD
[(tests)-352.1(if)-359.4(the)]TJ
-19.9631 -1.1116 TD
[(variables)-341.7(were)-335.9(not)-331.7(normally)-334(distributed.)]TJ
1.0137 -1.1174 TD
[(Between-group)-371.1(analyses)-369.1(were)-364.7(performed)-370.5(using)]TJ
/F6 1 Tf
19.6867 0 TD
(t)Tj
/F5 1 Tf
.2822 0 TD
[(-tests)-364.7(or)]TJ
-20.9826 -1.1116 TD
[(MannWhit)-8.8(ney)]TJ
/F6 1 Tf
6.9462 0 TD
(U)Tj
/F5 1 Tf
1.3651 0 TD
[(tests)-651.6(for)-648.3(the)-649.7(individual)-652(time)-652.1(points.)]TJ
-8.3113 -1.1116 TD
[(Analysis)-402.4(of)-399.6(covariances)-403.7(\(ANCOVAs\))-401(was)-396.8(used)-402.8(to)-394(test)-397.3(for)]TJ
0 -1.1174 TD
[(interventio)-9.2(n)-369.7(effects)-379.7(over)-379.9(time,)-373.4(controlling)-376.6(for)-377.6(baseline)-381(dif-)]TJ
0 -1.1116 TD
[(ferences,)-344.9(interaction)-338.6(effects)-339.4(between)-334.7(baseline)-340.7(and)-338.5(interven-)]TJ
T*
[(tion,)-376.7(and)-373.1(age.)-371.9(Effect)-373.1(sizes)-376.2(were)-376.2(given)-369.7(as)-377.5(eta)-368.6(squared)-378.4(\()]TJ
/F14 1 Tf
22.6702 0 TD
(Z)Tj
/F5 1 Tf
7.3823 0 0 6.5614 542.7211 439.0865 Tm
(2)Tj
9.843 0 0 9.843 546.4628 434.7211 Tm
(\).)Tj
-23.7127 -1.1174 TD
[(Differences)-564.7(in)-555.3(adequate)-560.8(relief)-562.1(between)-559.4(the)-557.5(groups)-559.3(were)]TJ
0 -1.1116 TD
[(calculated)-380.1(using)-368.3(the)-373.2(chi-square)-377.2(test.)-371.9(Further)-371.6(subgroup)-371.5(ana-)]TJ
T*
[(lyses)-375(with)-374.2(respect)-379.7(to)-370.9(tumor)-375.5(type)-374.3(and)-373.1(surgery)-371.5(method)-377.8(were)]TJ
T*
[(performed)-266.8(for)-262.4(the)-263.8(primary)-263.6(outcome)-264.8(measures)-266.5(only.)-261.4(For)-262.3(each)]TJ
0 -1.1174 TD
[(time)-594.5(point)-587.5(between-group)-589(analyses)-593.8(\(SC)-585.9(vs.)-592.9(yoga\))-588.4(were)]TJ
0 -1.1116 TD
[(conducted)-341.8(using)]TJ
/F6 1 Tf
6.9635 0 TD
(t)Tj
/F5 1 Tf
.2765 0 TD
(-tests.)Tj
/F13 1 Tf
8.9663 0 0 8.9663 313.0582 347.0172 Tm
[(Ethical)-338.9(and)-335.7(legal)-329.7(considerations)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 330.5763 Tm
[(All)-252.1(procedures)-256.2(performed)-249.5(in)-250(the)-252.3(study)-247.3(were)-255.2(in)-250(accordance)]TJ
-1.0137 -1.1116 TD
[(with)-420.2(the)-419.3(national)-420.5(regulation,)-426.1(the)-413.5(Helsinki)-425.7(declaration,)-423.7(and)]TJ
0 -1.1174 TD
[(the)-511.4(International)-513.6(Conference)-512(on)-509(Harmonization)-515.6(guideline)]TJ
0 -1.1116 TD
[(for)-458.2(Good)-454.5(Clinical)-461.9(Practice.)-460.5(Medical)-455.9(ethical)-460.8(approval)-454.7(was)]TJ
T*
[(obtained)-754.4(from)-748.6(the)-747.6(METOPP)-753.5(Tilburg)-752.1(\(Study)-749.5(No.)-743.8(NL)]TJ
0 -1.1174 TD
[(41230.028.12)-6.4(;)-306.5(M490\).)-303.6(Trial)-313.4(Registration)-310.6(Number)-309.4(was)-310.4(NTR)]TJ
0 -1.1116 TD
[(3701,)-336.2(24)-330.5(November)-341.5(2012)-332.7(\(www.trialregister.nl\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 242.8724 Tm
(Results)Tj
/F13 1 Tf
0 -1.8336 TD
[(Study)-338.6(population)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 209.9905 Tm
[(The)-334(time)-329.6(needed)-332.6(to)-330.6(recruit)-332.8(the)-327.1(calculated)-339.8(number)-331.5(of)-330.5(104)]TJ
-1.0137 -1.1116 TD
[(women)-308.3(in)-307.6(the)-309.9(study)-304.9(was)-310.4(originally)-306.4(estimated)-314.3(at)-303(2)-306.4(years)-312.9(and)]TJ
0 -1.1174 TD
[(recruitmen)-10.2(t)-352.6(was)-356.5(planned)-361.5(at)-354.8(one)-355.8(hospital)-355.8(only)-355.9(\(St.)-358(Jansdal\).)]TJ
0 -1.1116 TD
[(Two)-351(years)-353.2(after)-353.5(the)-344.4(start)-352.3(of)-347.7(the)-350.2(study,)-348.7(only)-350.1(half)-351.2(\()]TJ
/F6 1 Tf
20.3951 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(52\))-348.9(of)]TJ
-21.7774 -1.1116 TD
[(the)-413.5(required)-420.1(number)-412.2(of)-411.1(women)-412(were)-416.5(recruited.)-414.5(In)-416.9(2015)-407.6(it)]TJ
T*
[(was)-327.7(therefore)-330.2(decided)-328.1(to)-324.9(start)-323.5(recruitment)-328.2(at)-326(two)-326.8(additional)]TJ
0 -1.1174 TD
[(centers,)-337.1(the)-327.1(Alexander)-336.9(Monro)-328.9(Hospital)-327.8(and)-332.8(Flevo)-329.2(Hospital.)]TJ
0 -1.1116 TD
[(Despite)-471.7(this)-471(effort,)-466.3(recruitmen)-10.2(t)-462(remained)-474.4(at)-470(a)-463(lower)-474.2(than)]TJ
T*
[(anticipated)-259.2(rate.)-252.2(As)-244.8(shown)-253.9(in)-250(Figure)-249.6(1,)-246.4(a)-249.9(total)-254.7(of)-244.1(239)-251(women)]TJ
0 -1.1174 TD
[(were)-341.6(assessed)-334.1(for)-337.3(eligibility,)-334.4(of)-336.2(which)-330.2(156)-337.4(were)-335.9(excluded.)]TJ
1.0137 -1.1116 TD
[(Of)-331.3(those)-329.1(excluded,)-332.7(22)-330.5(did)-326(not)-326(meet)-330.6(the)-332.9(inclusion)-328.1(criteria)]TJ
-1.0137 -1.1116 TD
[(and)-390.4(134)-389.2(declined)-392.7(participation)-398.6(for)-389.1(several)-391.2(reasons)-395.5(\(not)-384.7(in-)]TJ
0 -1.1174 TD
[(terest)-9(ed)-320.1(in)-319.1(yoga)-316.6([)]TJ
/F6 1 Tf
7.1478 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(29],)-317.7(too)-320.2(much)-323.6(to)-319.1(participate)-322.5(in)-324.9(a)-319(study)]TJ
-8.5359 -1.1116 TD
([)Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(16],)-381.1(too)-377.8(long)-378.9(a)-376.6(travel)-383.5(distance)-381(to)-376.7(the)-379(hospital)-384.6([)]TJ
/F6 1 Tf
19.6003 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(12],)Tj
-22.7105 -1.1116 TD
[(and)-298.2(unknown)-296.6(reason)-296.7([)]TJ
/F6 1 Tf
9.0024 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(77]\).)-295.8(After)-295.6(4)-294.8(years,)-299(it)-296.2(was)-293.1(decided)]TJ
ET
62.022 709.512 239.131 .22681 re
f
62.022 383.017 239.131 .28348 re
f
62.022 670.79 239.131 .28345 re
f
BT
/F12 1 Tf
9.845 0 0 9.845 72.1701 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(1.)Tj
/F12 1 Tf
1.2496 0 TD
[(Yoga)-332.5(Program)-335.5(for)-332.2(Women)-337.3(with)-334.7(Breast)]TJ
-1.5203 -1.0135 TD
[(Cancer:)-331.6(Overview)-338(of)-331.2(Class)-333.7(Content)]TJ
/F6 1 Tf
-3.7603 -3.864 TD
(Content)Tj
6.3632 2.0212 TD
[(Time)-334.2(allotted)]TJ
.0058 -1.0135 TD
(\(approximate)Tj
1.7794 -1.0077 TD
[(min\))-5872.9(Description)]TJ
/F5 1 Tf
-8.1483 -1.9118 TD
(Breathing)Tj
.9098 -1.0077 TD
(awareness)Tj
0 -1.0135 TD
(\(pranayama\))Tj
7.6531 2.0212 TD
[(15)-2581.8(Warming)-334.1(up)-336(and)-332.4(free)]TJ
4.4917 -1.0077 TD
[(movements)-336.1(to)-336.2(facilitate)]TJ
0 -1.0135 TD
[(deep)-328.8(breathing)-328.3(followed)-332.7(by)]TJ
T*
[(three)-335.7(breathing)-334.1(techniques:)]TJ
0 -1.0077 TD
[(Deep)-335.4(Yogic,)-333(Ujjayi,)-340.1(and)]TJ
0 -1.0135 TD
[(Pigeon)-335.3(breath.)]TJ
-13.0546 -1.0135 TD
[(Energy)-336.5(block)]TJ
.9098 -1.0135 TD
(release)Tj
7.6531 1.0135 TD
[(15)-2581.8(Energy)-336.5(block)-334.5(release)-334.1(1)]TJ
4.4917 -1.0135 TD
[(sequences)-335.7(\(EBR1:)-337.5(to)]TJ
0 -1.0077 TD
[(balance)-334.3(mind)-339.3(and)]TJ
0 -1.0135 TD
[(emotions\),)-337.3(followed)-332.7(by)]TJ
T*
[(energy)-336.5(block)-334.5(release)-334.1(3)]TJ
T*
[(sequences)-335.7(\(EBR3:)-337.5(nourish)]TJ
0 -1.0077 TD
[(warmth)-337.5(and)-332.4(compassion\).)]TJ
-13.0546 -1.0135 TD
(Body)Tj
.9098 -1.0135 TD
(awareness)Tj
0 -1.0077 TD
(\(asana\))Tj
7.6531 2.0212 TD
[(30)-2581.8(Soft)-274.6(movement)-283.4(and)-274.8(stretching)]TJ
4.4917 -1.0135 TD
[(in)-336.2(easier)-331.9(sitting)-335.7(or)-336(lying)]TJ
0 -1.0077 TD
[(postures,)-334.8(followed)-338.5(by)-330.2(the)]TJ
0 -1.0135 TD
[(Prithvi)-335.5(Namaskar)-335.7(sequence)]TJ
T*
[(and)-332.4(alternately)]TJ
T*
[(Setubhandasana,)-339.6(Ardha)]TJ
0 -1.0077 TD
[(Matseyendrasana,)-342.6(Shava)]TJ
0 -1.0135 TD
[(Udarakarshanasana,)-339.8(or)]TJ
T*
[(Viparita)-334.1(Karani)-337.5(postures.)]TJ
-13.0546 -1.0135 TD
(Relaxation)Tj
.9098 -1.0077 TD
(\(savasana\))Tj
7.6531 1.0077 TD
[(15)-2581.8(Guided)-336.3(relaxation/)]TJ
4.4917 -1.0077 TD
[(visualization)-322.3(exercises)-324.4(with)]TJ
0 -1.0135 TD
[(specic)-338.5(focus)-334.2(on)-330.2(either)]TJ
T*
[(remaining)-335.2(tension)-336.5(in)-330.4(the)]TJ
0 -1.0077 TD
[(body,)-335.6(breathing,)-331.7(body)]TJ
0 -1.0135 TD
[(posture,)-334(or)-336(trust.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(944)Tj
48.2754 0 TD
[(JONG)-329.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
60 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 319.6913 Tm
0 0 0 rg
0 Tc
0 Tw
[(to)-255.8(stop)-257.8(recruitment)-259.1(for)-256.7(the)-258(study)-253.1(ending)-255.6(up)-255.6(with)-259(a)-255.7(total)-254.7(of)-255.6(83)]TJ
0 -1.1116 TD
[(women)-417.7(that)-420.5(were)-416.5(randomized)-419(in)-417(the)-413.5(study)-420.1(\(Fig.)-416.7(1\).)-414.5(Since)]TJ
T*
[(women)-452.3(enrolled)-449.1(were)-451.1(stratied)-450(into)-453.9(4)-444.6(strata,)-450.1(each)-451.4(with)-449(a)]TJ
0 -1.1174 TD
[(random)-406.4(block)-404.2(size)-409.8(of)-405.3(10,)-403.1(it)-399.9(happened)-409.7(by)-405.4(coincidence)-409.9(that)]TJ
0 -1.1116 TD
[(more)-415.7(women)-412(were)-416.5(allocated)-412.4(to)-411.3(the)-413.5(yoga)-414.5(program)-413.2(\()]TJ
/F6 1 Tf
21.5759 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(47\))Tj
-22.9582 -1.1116 TD
[(than)-351.3(to)-347.9(SC)-348.6(\()]TJ
/F6 1 Tf
5.1089 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(36\).)-346.5(Five)-351.1(women)-348.6(in)-347.9(SC)-348.6(did)-349(not)-349(receive)-352.3(the)]TJ
-6.4969 -1.1174 TD
[(allocated)-504.5(intervention)-505.6(as)-498.5(planned,)-503.2(but)-504.5(participated)-502.2(in)-497.7(the)]TJ
0 -1.1116 TD
[(yoga)-345.4(program)-349.9(during)-340.8(the)-344.4(course)-348.5(of)-342(the)-344.4(study.)-342.9(Furthermore,)]TJ
T*
[(two)-275(women)-273.7(\(yoga)-271.6(program:)]TJ
/F6 1 Tf
11.4906 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(1;)-267.3(SC:)]TJ
/F6 1 Tf
2.8223 0 TD
(N)Tj
/F7 1 Tf
.8352 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(1\))-272.9(dropped)-273.8(out)-268.4(of)]TJ
-17.2503 -1.1116 TD
[(the)-338.7(study)-333.7(\(Fig.)-330.3(1\).)]TJ
1.0137 -1.1174 TD
[(As)-400.3(shown)-403.6(in)-399.7(Table)-400.8(2,)-402(about)-398.5(two-third)-402.8(of)-399.6(the)-402(women)-400.4(in)]TJ
-1.0137 -1.1116 TD
[(both)-488.3(groups)-484.4(had)-482.5(undergone)-484.5(lumpectomy,)-486(and)-488.3(about)-484.9(one-)]TJ
T*
[(third)-420.4(mastectomy.)-417.9(All)-413.4(women)-417.7(received)-416.7(chem)-8(otherapy,)-412.1(the)]TJ
0 -1.1174 TD
[(majority)-449.3(in)-445.8(both)-442.3(groups)-449.9(before)-446.6(surgery)-446.4(\(neoadjuvant\).)-447.7(PP)]TJ
0 -1.1116 TD
[(analysis)-506.3(demonstrated)-507.6(that)-501.2(groups)-501.7(were)-508.7(comparable)-506.6(with)]TJ
T*
[(respect)-621.6(to)-612.9(most)-616.1(demographic)-615.9(characteristics,)-626(except)-615(for)]TJ
0 -1.1174 TD
[(scheduled)-410.8(adjuvant)-408.8(hormone)-407.5(therapy)-407.6(and)-407.6(higher)-411.1(treatment)]TJ
0 -1.1116 TD
[(preference)-339.3(for)-337.3(SC)-331.4(in)-336.4(women)-331.3(in)-336.4(the)-332.9(yoga)-333.9(group)-333.8(\(Table)-338.5(2\).)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 59.7543 105.9023 Tm
(Fatigue)Tj
/F5 1 Tf
9.843 0 0 9.843 69.7323 89.4614 Tm
[(A)15.3(s)-271.6(sh)26.8(o)16.2(w)15.3(n)-277.6(i)16.1(n)-271.8(T)15(a)15(b)16.2(le)-262.7(3)16.2(,)-274.1(t)16.1(h)16.2(e)-273(p)16.2(ri)26.5(m)15(a)15(r)16.2(y)-271.8(o)0(u)26.6(t)16.1(c)15(o)16.2(me)24.2(,)-268.4(g)0(e)25.4(n)16.2(e)15(r)16.2(al)-262.7(f)16.2(a)15(t)16.1(i)0(g)26.5(u)16.2(e)]TJ
-1.0137 -1.1174 TD
-.0158 Tc
[(\()-15.8(d)10.8(imen)-15.8(s)11(i).3(on)-253(of)-247.3(MFI)-15.8(\))-236.8(was)-247.1(s)-15.8(i)10.9(gni)-15.8()10.8(can)-15.8(t)10.7(l).3(y)-247.3(h).4(i)-15.8(g)10.7(her)-247.3(i)-15.8(n)-237(t).3(he)-248.4(y)-15.8(o)10.8(ga)-248.4(gr)-15.8(o)10.8(u).4(p)]TJ
0 -1.1116 TD
-.0159 Tc
[(a)-15.9(t)-238.3(T)-15.9(0)9.5(,)-249.7(c)-.9(o)-15.9(m)9.5(pared)-253.1(w)-15.9(i)9.7(t).2(h)-253.1(S).4(C)-254.2(onl)-15.9(y)10.6(.)-249.7(Up)-15.9(o)10.7(n)-253.1(PP)-253(anal)-15.9(y)10.6(s).5(is)-15.9(,)-239.1(a)-254.3(si)-15.9(g)10.6(n).3(ic)-15.9(a)8.4(nt)]TJ
T*
-.0157 Tc
[(i)-15.7(n)10.8(crea)-15.7(s)9.9(e)-277.1(i)-15.7(n)-265.7(ge)-15.7(n)9.7(e)-.7(ral)-281.9(f).5(at)-15.7(i)10.6(gue)-282.9(was)-281.5(obs)-15.7(e)9.9(rved)-281.7(f).5(r)-15.7(o)10.9(m)-277.2(T)-.7(0)-281.7(t).4(o)-281.7(T)-.7(1)-276(i).4(n)-281.7(S).6(C)]TJ
25.5097 26.7308 TD
0 Tc
(\()Tj
/F6 1 Tf
.4838 0 TD
(p)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
-.0162 Tc
[(0)-16.2(.)13.8(0)-16.2(0)10.4(6\),)-353.7(but)-351.5(not)-351.5(in)-351.4(the)-352.5(yoga)-352.5(gro)-16.2(u)10.4(p)-351.4(\()]TJ
/F6 1 Tf
14.2092 0 TD
0 Tc
(p)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
-.0156 Tc
[(0.17)-15.6(5)11(\)).6(.)-347.3(H)-15.6(o)10.1(w)-.3(eve)-15.6(r)9.9(,)]TJ
-17.4001 -1.1116 TD
[(no)-350.9(s)-15.7(i)11(gni)-15.7()10.9(can)-15.7(t)-340.6(d).5(i)-15.7(f)10.8(fer)-15.7(e)9.8(nce)-357.8(w)-.4(as)-356.4(obse)-15.7(r)9.8(ved)-356.6(i).4(n)-350.9(g)-15.7(e)9.7(n).5(era)-15.7(l)-341.7(fa)-15.7(t)9.6(i).4(gu)-15.7(e)-341.6(b).5(e-)]TJ
T*
[(twee)-15.7(n)-485.6(t).4(he)-496(g)-15.7(r)10.9(oup)-15.7(s)-484.2(a)-.7(t)-495(T)-.7(1)-500.6(\().5(Tabl)-15.7(e)-485.7(3\).)-497.2(At)-500.7(T2,)-497.2(g).5(ener)-15.7(a)9.8(l)-495(fa)-15.7(t)9.6(i).4(gu)-15.7(e)]TJ
0 -1.1174 TD
[(remai)-15.7(n)10.8(e)-.7(d)-241.4(h).5(igh)-241.4(i).3(n)-241.4(S).6(C.)-243.8(With)-241.4(res)-15.7(p)11.1(ect)-241.6(to)-241.4(othe)-15.7(r)-226.4(d)-15.7(i)10.8(mens)-15.7(i)11(ons)-241.2(of)-241.4(MFI)]TJ
0 -1.1116 TD
-.0159 Tc
[(and)-477.8(F).4(QL)-15.9(,)-465.1(bot)-15.9(h)-467.5(group)-15.9(s)-467.2(w)-.6(ere)-478.9(c)-.9(om)-15.9(p)9.5(a)-.9(rab)-15.9(l)10.6(e)-478.9(a)-.9(t)-477.9(T)-.9(0.)-474.3(S)-15.9(i)10.7(gni)-15.9()10.7(cant)]TJ
T*
[(dif)-15.9(f)10.8(eren)-15.9(c)9.5(e)-.9(s)-437.3(i)-15.9(n)-427.2(t).1(he)-438.6(do)-15.9(m)9.5(a)-.9(ins)-443(o).3(f)-437.4(f).3(a)-15.9(t)9.4(igue)-444.4(\(bot)-15.9(h)-427.2(M)-.6(FI)-437.4(an)-15.9(d)-427(F).4(QL\))]TJ
0 -1.1174 TD
[(were)-490.5(f)-15.9(o)10.7(und)-489.3(wit)-15.9(h)10.6(in)-489.3(th)-15.9(e)-474.3(g)-15.9(r)10.7(oups)-489.1(a)-15.9(t)-474.4(e)-15.9(i)9.4(the)-15.9(r)-474.2(T)-15.9(1)-474.3(o)-15.9(r)-478.8(T2)-489.3(month)-15.9(s)10.9(,)]TJ
0 -1.1116 TD
-.0156 Tc
[(compa)-15.6(r)9.9(ed)-247.1(wi)-15.6(t)10.7(h)-247.1(T0)-247.1(\()-15.6(T)9.8(able)-248.2(3)-15.6(\))11(.)-249.4(H)-.3(owev)-15.6(e)9.8(r).6(,)-249.4(for)-247.1(n)-15.6(o)11(ne)-248.2(of)-252.8(thes)-15.6(e)-237.6(o).6(ther)]TJ
T*
-.0159 Tc
[(fati)-15.9(g)10.6(u).3(e)-513.5(s).5(ubs)-15.9(c)9.7(a)-.9(le)-15.9(s)-497.1(s).5(i)-15.9(g)10.6(ni)-15.9(c)9.7(ant)-512.5(d).3(if)-15.9(f)10.8(e)-.9(ren)-15.9(c)9.5(es)-512.1(coul)-15.9(d)-496.3(b).3(e)-513.5(obs)-15.9(e)9.7(rved)]TJ
T*
[(betw)-15.9(e)8.7(e)-.9(n)-333.8(t).2(he)-334.9(g)-15.9(r)10.7(oup)-15.9(s)-323.2(a)-.9(t)-333.9(T)-.9(1)-333.8(o).3(r)-339.5(T)-.9(2)-333.8(\().3(Tabl)-15.9(e)-324.7(3\).)]TJ
1.0137 -1.1174 TD
0 Tc
[(Additional)-514.7(\(ANCOVA\))-521(analyses)-524.7(demonstrated)-519.1(that)-518.4(for)]TJ
-1.0137 -1.1116 TD
[(three)-445.7(domains)-442(of)-445.7(MFI,)-439.4(there)-445.7(was)-448.6(a)-440(signicant)-445.4(interaction)]TJ
T*
[(between)-455.7(the)-459.6(intervention)-453.8(effect)-459.4(over)-460.6(time)-456.3(and)-453.7(the)-453.8(age)-460.6(of)]TJ
0 -1.1174 TD
[(women,)-196.5(that)-195.9(is,)-195.6(the)-194.7(higher)-197.9(the)-200.4(age)-195.7(the)-194.7(higher)-197.9(the)-194.7(score)-197.7(on)-198(MFI)]TJ
0 -1.1116 TD
[(\(physical)-461.5(fatigue:)]TJ
/F6 1 Tf
7.6662 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(0.0316,)-461.6(reduced)-460.4(activity:)]TJ
/F6 1 Tf
10.857 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(0.0017,)Tj
-21.2879 -1.1116 TD
[(reduced)-558.3(motivation:)]TJ
/F6 1 Tf
8.9218 0 TD
(p)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.0099\).)-554.9(Subsequent)-560.3(\(ANCOVA\))]TJ
-10.3041 -1.1174 TD
[(subgroup)-285.1(analyses)-294.3(for)-285.5(age)-287.9(groups)-288.6(\(cutoff)-291.1(point:)]TJ
/F7 1 Tf
19.4793 0 TD
(<)Tj
/F5 1 Tf
.5472 0 TD
[(53)-290.2(vs.)]TJ
/F7 1 Tf
2.7128 0 TD
()Tj
/F5 1 Tf
.5529 0 TD
(53)Tj
-23.2922 -1.1116 TD
[(years\))-169.9(did)-164.7(not)-164.7(demonstrate)-172.4(signicant)-168.9(differences)-172.1(between)-173.5(the)]TJ
T*
[(yoga)-282(and)-280.9(SC)-279.5(group)-281.9(in)-278.8(MFI)-280.5(and)-280.9(FQL)-281.7(domains.)-284.2(Further)-279.5(addi-)]TJ
T*
[(tional)-238.5(subgroup)-239(analyses)-242.4(with)-241.7(respect)-241.5(to)-238.5(specic)-241.4(tumor)-237.2(types)]TJ
0 -1.1174 TD
[(and)-246.4(type)-247.6(of)-244.1(surgery)-250.5(and)-246.4(the)-246.5(primary)-252.1(outcome)-247.6(general)-253.2(fatigue)]TJ
0 -1.1116 TD
[(did)-308.7(not)-308.7(demonstrate)-316.4(any)-309.7(signicant)-312.9(differences)-316.1(between)-311.7(the)]TJ
T*
[(two)-217.4(groups)-213.7(\(results)-217.1(not)-216.5(shown\).)-218(However,)-216.8(sample)-217.5(sizes)-220.7(in)-215.4(the)]TJ
0 -1.1174 TD
[(subgroup)-469.4(analysis)-466(were)-474.1(probably)-465.1(too)-470(small)-468.7(to)-468.9(detect)-471.1(any)]TJ
0 -1.1116 TD
[(possible)-263.3(signicant)-261(differences.)]TJ
ET
q
361.077 0 0 381.713 59.754 350.305 cm
/Im1 Do
Q
BT
/F11 1 Tf
9.845 0 0 9.845 433.7007 542.8912 Tm
[(FIG.)-331(1.)]TJ
/F5 1 Tf
4.1116 0 TD
[(Flow)-333(chart)-335.7(of)]TJ
-4.1116 -1.0135 TD
[(women)-330.6(in)-336.2(the)-332.6(study.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(TRIAL)-336.6(OF)-337.5(YOGA)-329.3(ON)-334.6(FATIGUE)-337.6(IN)-335.1(BREAST)-338.7(CANCER)-28130(945)]TJ
ET
endstream
endobj
62 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͜c7>ll,&4~^bki[pfOZ2Zڏ*)u
\$[K[ImU+